At Koncare Biotech, we celebrate a new milestone that reinforces our trajectory in the field of digestive health. The international magazine Life Sciences Review Europe has granted us the Award for the Best Nutraceutical Treatment in Digestive Health in Europe 2025, a recognition that highlights our dedication to innovation, scientific research, and the improvement of intestinal well-being.
This award acknowledges years of committed work developing natural, clinically proven products capable of addressing digestive disorders from an integrative perspective. A milestone that consolidates Koncare Biotech as a European reference in nutraceutical innovation and digestive health. Here’s how the prestigious magazine explained how we achieved this award in digestive health:
Koncare Biotech: Pioneering the future of digestive health through nutraceutical innovation
Under the leadership of its founder and CEO, Concha Pérez, Koncare Biotech has established itself as a pioneering force in the treatment of digestive disorders. Founded in 2019 with the aim of improving patients’ quality of life, the company stands at the forefront of developing natural products supported by strict quality standards.
This visionary company is making great strides in the nutraceutical industry, combining clinical research, deep knowledge of gut health, and cutting-edge science to provide effective solutions. Specializing in digestive pathologies, Koncare applies a holistic and integrative approach that tackles the real causes of common conditions such as Irritable Bowel Syndrome (IBS), intestinal dysbiosis, and Metabolic-Associated Fatty Liver Disease (MAFLD)—clearly distinguishing itself from other market players.
According to Concha Pérez, what truly makes Koncare unique is its ability to merge applied clinical research with an integrative vision of health. Its products are backed by solid scientific foundations and are personalized for each digestive condition. This evidence-based and individualized approach enables the company to address complex, multifactorial digestive problems, anticipating the latest trends in neurogastroenterology and gut microbiota.
“We incorporated the principles of neurogastroenterology and gut microbiota long before they became mainstream,” Pérez notes, reaffirming the company’s commitment to continuous innovation
Thanks to this forward-looking vision, Koncare has expanded internationally, signing a distribution agreement in the United Arab Emirates with Dr. Safwan Nached, CEO of Pharmapal, further strengthening its global presence.
Koncare products that change lives
The company’s product portfolio perfectly reflects its philosophy of clinical innovation. Among its most notable formulations is Disibex Forte, a product designed to treat functional dyspepsia, which goes beyond symptomatic relief by targeting the underlying pathophysiological mechanisms.
Disibex Forte combines probiotic strains, plant extracts, digestive enzymes, and immune modulators, making it a one-of-a-kind product in its category. It also plays an essential role as an adjuvant in the eradication of Helicobacter pylori and in the prevention and treatment of traveler’s diarrhea.
Another key product, Metabok, offers an integrative solution for MAFLD, a condition often linked to metabolic and cardiovascular problems. Its formulation is designed to modulate gut microbiota, reduce hepatic fat accumulation, and improve liver and cardiovascular health, incorporating probiotics, vitamin E, phytolyzed silymarin, and resveratrol.
These innovations reflect Koncare’s unwavering commitment to efficacy, safety, and pathophysiology-based therapeutic solutions.
The scientific foundation behind its products is supported by ongoing research and collaboration with clinical groups and research centers studying the role of microbiota in digestive, functional, and immune-related diseases. Pérez emphasizes that continuous education and the swift transfer of scientific findings into clinical practice are essential to the company’s working philosophy.
Examples such as SIIK, a product focused on the integration of neurogastroenterology, demonstrate Koncare’s commitment to supporting patients suffering from gut-brain interaction disorders, such as Irritable Bowel Syndrome.
Beyond product innovation, Koncare’s success is also rooted in the trust of healthcare professionals, strengthened through ongoing dialogue and specialized training programs for doctors, nutritionists, and pharmacists, promoting the rational and evidence-based use of nutraceuticals.
Thanks to its unique combination of research, clinical expertise, and dedication to digestive health, Koncare Biotech stands as a leader in the nutraceutical treatment of digestive pathologies in Europe and beyond, earning this prestigious award in digestive health.